 Samuel Dominguez
Concepts (713)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 27 | 2025 | 177 | 7.940 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 20 | 2025 | 91 | 5.070 |
Why?
| | Respiratory Tract Infections | 23 | 2025 | 390 | 5.060 |
Why?
| | Enterovirus D, Human | 16 | 2025 | 85 | 4.530 |
Why?
| | Multiplex Polymerase Chain Reaction | 12 | 2025 | 54 | 4.510 |
Why?
| | Myelitis | 14 | 2025 | 107 | 4.000 |
Why?
| | Disease Outbreaks | 23 | 2025 | 395 | 3.760 |
Why?
| | Molecular Diagnostic Techniques | 10 | 2025 | 105 | 3.000 |
Why?
| | Enterovirus | 11 | 2019 | 86 | 2.870 |
Why?
| | Coronavirus | 10 | 2015 | 47 | 2.760 |
Why?
| | Meningitis | 8 | 2022 | 79 | 2.750 |
Why?
| | Child, Preschool | 80 | 2025 | 11074 | 2.740 |
Why?
| | Central Nervous System Viral Diseases | 7 | 2025 | 79 | 2.690 |
Why?
| | Polymerase Chain Reaction | 14 | 2025 | 1062 | 2.570 |
Why?
| | Influenza, Human | 13 | 2023 | 622 | 2.570 |
Why?
| | Neuromuscular Diseases | 7 | 2025 | 132 | 2.550 |
Why?
| | Child | 106 | 2025 | 21935 | 2.540 |
Why?
| | Infant | 66 | 2025 | 9465 | 2.480 |
Why?
| | Anti-Bacterial Agents | 19 | 2025 | 1809 | 2.430 |
Why?
| | Encephalitis | 11 | 2022 | 136 | 2.310 |
Why?
| | Gastroenteritis | 5 | 2023 | 69 | 2.140 |
Why?
| | Clostridium Infections | 6 | 2024 | 73 | 2.140 |
Why?
| | Anti-Infective Agents | 5 | 2022 | 255 | 2.090 |
Why?
| | Colorado | 41 | 2025 | 4565 | 1.920 |
Why?
| | Influenza A Virus, H1N1 Subtype | 7 | 2020 | 148 | 1.870 |
Why?
| | Immunoglobulins, Intravenous | 6 | 2020 | 132 | 1.860 |
Why?
| | Bacteremia | 4 | 2025 | 214 | 1.860 |
Why?
| | Pleural Effusion | 2 | 2025 | 54 | 1.800 |
Why?
| | Diarrhea | 7 | 2023 | 184 | 1.730 |
Why?
| | Feces | 9 | 2023 | 484 | 1.720 |
Why?
| | Blood Culture | 2 | 2025 | 23 | 1.650 |
Why?
| | Paralysis | 4 | 2018 | 71 | 1.590 |
Why?
| | Hospitals, Pediatric | 12 | 2024 | 508 | 1.560 |
Why?
| | Coronavirus Infections | 9 | 2020 | 364 | 1.530 |
Why?
| | Bacteria | 8 | 2025 | 858 | 1.510 |
Why?
| | Nervous System Diseases | 5 | 2020 | 266 | 1.500 |
Why?
| | Humans | 169 | 2025 | 137585 | 1.470 |
Why?
| | Bacteriological Techniques | 2 | 2025 | 73 | 1.460 |
Why?
| | Infliximab | 4 | 2019 | 111 | 1.430 |
Why?
| | Antimicrobial Stewardship | 3 | 2025 | 118 | 1.420 |
Why?
| | Streptococcus pneumoniae | 4 | 2025 | 169 | 1.380 |
Why?
| | Respiratory Syncytial Virus, Human | 4 | 2025 | 74 | 1.370 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 35 | 1.370 |
Why?
| | Simplexvirus | 3 | 2020 | 80 | 1.340 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2025 | 128 | 1.300 |
Why?
| | Male | 107 | 2025 | 67762 | 1.290 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 92 | 1.280 |
Why?
| | Community-Acquired Infections | 5 | 2025 | 174 | 1.260 |
Why?
| | Retrospective Studies | 41 | 2025 | 15657 | 1.190 |
Why?
| | Streptococcus pyogenes | 3 | 2025 | 45 | 1.180 |
Why?
| | Epidemiological Monitoring | 3 | 2020 | 60 | 1.150 |
Why?
| | Pandemics | 12 | 2025 | 1639 | 1.150 |
Why?
| | Streptococcal Infections | 3 | 2025 | 151 | 1.150 |
Why?
| | Stevens-Johnson Syndrome | 3 | 2017 | 39 | 1.140 |
Why?
| | Female | 89 | 2025 | 73304 | 1.100 |
Why?
| | Chiroptera | 4 | 2014 | 56 | 1.100 |
Why?
| | Intensive Care Units, Pediatric | 4 | 2021 | 233 | 1.080 |
Why?
| | Adolescent | 49 | 2025 | 21513 | 1.080 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 63 | 1.070 |
Why?
| | Child, Hospitalized | 3 | 2024 | 49 | 1.070 |
Why?
| | Bacterial Infections | 2 | 2020 | 250 | 1.070 |
Why?
| | Nasopharynx | 5 | 2023 | 76 | 1.060 |
Why?
| | Spike Glycoprotein, Coronavirus | 8 | 2022 | 109 | 1.050 |
Why?
| | Picornaviridae Infections | 5 | 2019 | 47 | 1.040 |
Why?
| | Otitis Media | 3 | 2024 | 165 | 1.030 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2025 | 23 | 0.930 |
Why?
| | Infant, Newborn | 20 | 2025 | 6079 | 0.920 |
Why?
| | Communicable Diseases | 2 | 2017 | 159 | 0.920 |
Why?
| | Respiratory Tract Diseases | 2 | 2024 | 184 | 0.910 |
Why?
| | Conjunctivitis, Bacterial | 1 | 2024 | 11 | 0.900 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2025 | 53 | 0.880 |
Why?
| | Sensitivity and Specificity | 11 | 2025 | 1946 | 0.870 |
Why?
| | Staphylococcus aureus | 2 | 2025 | 450 | 0.860 |
Why?
| | Osteomyelitis | 3 | 2024 | 132 | 0.860 |
Why?
| | Hospitalization | 15 | 2024 | 2199 | 0.850 |
Why?
| | Pneumonia, Bacterial | 1 | 2025 | 116 | 0.850 |
Why?
| | RNA, Viral | 11 | 2020 | 656 | 0.830 |
Why?
| | Antiviral Agents | 6 | 2020 | 744 | 0.820 |
Why?
| | Pneumonia, Mycoplasma | 3 | 2024 | 57 | 0.810 |
Why?
| | Coronaviridae | 2 | 2014 | 3 | 0.800 |
Why?
| | Parechovirus | 3 | 2019 | 8 | 0.780 |
Why?
| | Drug Resistance, Bacterial | 3 | 2022 | 186 | 0.760 |
Why?
| | Nervous System Malformations | 1 | 2022 | 42 | 0.720 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 110 | 0.720 |
Why?
| | Virus Cultivation | 2 | 2018 | 29 | 0.710 |
Why?
| | Rhinovirus | 5 | 2017 | 58 | 0.700 |
Why?
| | Enteropathogenic Escherichia coli | 1 | 2020 | 1 | 0.700 |
Why?
| | Enterotoxigenic Escherichia coli | 1 | 2020 | 5 | 0.700 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.700 |
Why?
| | Acute Disease | 12 | 2025 | 1007 | 0.690 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.680 |
Why?
| | Hospitals | 4 | 2021 | 691 | 0.670 |
Why?
| | Adenoviridae Infections | 2 | 2023 | 17 | 0.660 |
Why?
| | Escherichia coli Infections | 1 | 2020 | 111 | 0.660 |
Why?
| | Cross Infection | 3 | 2019 | 256 | 0.650 |
Why?
| | Acyclovir | 1 | 2020 | 101 | 0.640 |
Why?
| | Serratia Infections | 1 | 2019 | 8 | 0.640 |
Why?
| | Serratia marcescens | 1 | 2019 | 16 | 0.630 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 24 | 0.630 |
Why?
| | Drug Utilization | 2 | 2017 | 169 | 0.620 |
Why?
| | Pneumonia | 1 | 2025 | 639 | 0.620 |
Why?
| | Receptors, Virus | 3 | 2017 | 83 | 0.620 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 14 | 0.620 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 34 | 0.620 |
Why?
| | Seasons | 10 | 2023 | 547 | 0.620 |
Why?
| | Syringes | 1 | 2019 | 44 | 0.610 |
Why?
| | Equipment Contamination | 1 | 2019 | 67 | 0.610 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 6 | 0.610 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 47 | 0.600 |
Why?
| | Kingella kingae | 1 | 2018 | 12 | 0.600 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 373 | 0.600 |
Why?
| | Coronary Vessels | 2 | 2018 | 248 | 0.600 |
Why?
| | Adenoviridae | 3 | 2023 | 193 | 0.600 |
Why?
| | Steroids | 1 | 2019 | 167 | 0.590 |
Why?
| | Herpes Simplex | 2 | 2018 | 95 | 0.590 |
Why?
| | Enterovirus A, Human | 1 | 2018 | 13 | 0.590 |
Why?
| | Fluoxetine | 1 | 2018 | 54 | 0.580 |
Why?
| | Microbial Sensitivity Tests | 3 | 2025 | 361 | 0.560 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2017 | 23 | 0.560 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 209 | 0.560 |
Why?
| | Escherichia coli | 2 | 2025 | 815 | 0.550 |
Why?
| | Immunologic Factors | 1 | 2019 | 236 | 0.540 |
Why?
| | Viruses | 5 | 2022 | 113 | 0.530 |
Why?
| | Time Factors | 10 | 2021 | 6828 | 0.510 |
Why?
| | Osteoarthritis | 1 | 2018 | 185 | 0.510 |
Why?
| | Viral Tropism | 2 | 2015 | 31 | 0.500 |
Why?
| | Molecular Epidemiology | 2 | 2017 | 68 | 0.500 |
Why?
| | Genome, Viral | 3 | 2016 | 144 | 0.490 |
Why?
| | Phylogeny | 9 | 2016 | 904 | 0.490 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 43 | 0.490 |
Why?
| | Mycoplasma pneumoniae | 3 | 2024 | 57 | 0.490 |
Why?
| | Catheter-Related Infections | 1 | 2016 | 92 | 0.480 |
Why?
| | Case-Control Studies | 9 | 2024 | 3556 | 0.470 |
Why?
| | Adenovirus Infections, Human | 1 | 2015 | 15 | 0.470 |
Why?
| | Bacterial Typing Techniques | 1 | 2015 | 44 | 0.470 |
Why?
| | Calcitonin | 1 | 2015 | 27 | 0.470 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 394 | 0.460 |
Why?
| | Caliciviridae Infections | 1 | 2015 | 20 | 0.460 |
Why?
| | Cohort Studies | 10 | 2024 | 5742 | 0.460 |
Why?
| | Muscle Hypotonia | 1 | 2015 | 33 | 0.460 |
Why?
| | Rotavirus Infections | 1 | 2015 | 43 | 0.460 |
Why?
| | Catheterization, Central Venous | 1 | 2016 | 112 | 0.460 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2025 | 48 | 0.450 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.440 |
Why?
| | Coronaviridae Infections | 1 | 2014 | 3 | 0.440 |
Why?
| | Whole Genome Sequencing | 1 | 2015 | 160 | 0.440 |
Why?
| | Prospective Studies | 8 | 2025 | 7604 | 0.430 |
Why?
| | Metapneumovirus | 2 | 2025 | 16 | 0.430 |
Why?
| | United States | 20 | 2025 | 14841 | 0.430 |
Why?
| | Motor Neurons | 1 | 2016 | 234 | 0.430 |
Why?
| | Rubulavirus Infections | 1 | 2013 | 2 | 0.430 |
Why?
| | Haemophilus Infections | 2 | 2024 | 42 | 0.430 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2025 | 234 | 0.420 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 698 | 0.420 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 147 | 0.420 |
Why?
| | Prevalence | 7 | 2025 | 2734 | 0.420 |
Why?
| | Fever | 6 | 2022 | 306 | 0.410 |
Why?
| | Neuraminidase | 3 | 2020 | 24 | 0.400 |
Why?
| | Coronavirus NL63, Human | 1 | 2012 | 3 | 0.390 |
Why?
| | Sequence Analysis, DNA | 8 | 2019 | 812 | 0.390 |
Why?
| | Betacoronavirus | 3 | 2020 | 270 | 0.380 |
Why?
| | Sepsis | 1 | 2018 | 617 | 0.380 |
Why?
| | Viral Load | 3 | 2024 | 466 | 0.380 |
Why?
| | Genotype | 4 | 2017 | 1916 | 0.380 |
Why?
| | Metagenomics | 5 | 2021 | 169 | 0.370 |
Why?
| | Viral Envelope Proteins | 1 | 2012 | 84 | 0.370 |
Why?
| | Treatment Outcome | 10 | 2024 | 10811 | 0.360 |
Why?
| | Recombination, Genetic | 1 | 2012 | 204 | 0.350 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 165 | 0.350 |
Why?
| | Genetic Variation | 2 | 2014 | 991 | 0.340 |
Why?
| | Cluster Analysis | 5 | 2021 | 499 | 0.340 |
Why?
| | Coinfection | 3 | 2022 | 137 | 0.340 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 13 | 0.330 |
Why?
| | Young Adult | 17 | 2024 | 13209 | 0.330 |
Why?
| | Staphylococcal Infections | 2 | 2025 | 400 | 0.320 |
Why?
| | Rodentia | 7 | 2010 | 57 | 0.320 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 630 | 0.320 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 500 | 0.320 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1171 | 0.310 |
Why?
| | Critical Care | 4 | 2021 | 601 | 0.300 |
Why?
| | Virus Internalization | 4 | 2017 | 49 | 0.290 |
Why?
| | beta-Lactamases | 2 | 2025 | 48 | 0.290 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2900 | 0.280 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.280 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 5472 | 0.280 |
Why?
| | Neoplasms | 3 | 2023 | 2671 | 0.280 |
Why?
| | Immunity, Innate | 1 | 2013 | 828 | 0.270 |
Why?
| | Algorithms | 4 | 2025 | 1704 | 0.270 |
Why?
| | HIV Infections | 5 | 2017 | 2836 | 0.270 |
Why?
| | Severity of Illness Index | 4 | 2024 | 2828 | 0.260 |
Why?
| | Diagnosis, Differential | 7 | 2020 | 1483 | 0.260 |
Why?
| | Mycoplasma hominis | 1 | 2006 | 4 | 0.260 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3284 | 0.250 |
Why?
| | Apolipoproteins E | 4 | 2016 | 83 | 0.250 |
Why?
| | Endocarditis, Bacterial | 1 | 2006 | 41 | 0.250 |
Why?
| | Virus Diseases | 1 | 2008 | 212 | 0.250 |
Why?
| | Murine hepatitis virus | 2 | 2016 | 16 | 0.250 |
Why?
| | Integrons | 1 | 2025 | 4 | 0.240 |
Why?
| | Paramyxoviridae Infections | 1 | 2025 | 13 | 0.240 |
Why?
| | Immunization | 2 | 2004 | 411 | 0.240 |
Why?
| | Enzyme Inhibitors | 3 | 2020 | 840 | 0.230 |
Why?
| | Critical Illness | 2 | 2025 | 811 | 0.230 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 127 | 0.230 |
Why?
| | Paraplegia | 2 | 2015 | 60 | 0.230 |
Why?
| | Methicillin Resistance | 1 | 2004 | 18 | 0.220 |
Why?
| | Coronary Aneurysm | 2 | 2024 | 14 | 0.220 |
Why?
| | Cellulitis | 1 | 2004 | 53 | 0.220 |
Why?
| | Guatemala | 1 | 2025 | 327 | 0.220 |
Why?
| | Meningitis, Haemophilus | 1 | 2003 | 6 | 0.210 |
Why?
| | Haemophilus influenzae type b | 1 | 2003 | 12 | 0.210 |
Why?
| | Musculoskeletal Diseases | 1 | 2025 | 78 | 0.210 |
Why?
| | Haemophilus Vaccines | 1 | 2003 | 30 | 0.210 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.210 |
Why?
| | Antigens, Viral | 3 | 2020 | 178 | 0.210 |
Why?
| | Clindamycin | 2 | 2018 | 15 | 0.210 |
Why?
| | Polysaccharides, Bacterial | 1 | 2003 | 70 | 0.210 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 539 | 0.210 |
Why?
| | Global Health | 2 | 2021 | 386 | 0.200 |
Why?
| | Medical Oncology | 2 | 2023 | 289 | 0.200 |
Why?
| | Risk Factors | 9 | 2021 | 10388 | 0.200 |
Why?
| | American Heart Association | 1 | 2024 | 306 | 0.200 |
Why?
| | Clinical Laboratory Techniques | 2 | 2020 | 97 | 0.200 |
Why?
| | Incidence | 4 | 2021 | 2804 | 0.200 |
Why?
| | Critical Pathways | 1 | 2024 | 96 | 0.200 |
Why?
| | Coronavirus 229E, Human | 1 | 2022 | 6 | 0.200 |
Why?
| | Hepatitis C | 4 | 2006 | 271 | 0.190 |
Why?
| | Canada | 3 | 2025 | 418 | 0.190 |
Why?
| | Disease Management | 3 | 2024 | 628 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 67 | 0.190 |
Why?
| | Logistic Models | 2 | 2018 | 2074 | 0.190 |
Why?
| | Pharyngitis | 1 | 2022 | 26 | 0.190 |
Why?
| | Vomiting | 2 | 2020 | 130 | 0.180 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2020 | 42 | 0.180 |
Why?
| | North America | 2 | 2016 | 313 | 0.180 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 861 | 0.180 |
Why?
| | Brain Diseases | 2 | 2020 | 141 | 0.180 |
Why?
| | Abdominal Pain | 2 | 2020 | 145 | 0.180 |
Why?
| | Meningoencephalitis | 2 | 2019 | 25 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 4 | 2018 | 3566 | 0.180 |
Why?
| | Lethargy | 1 | 2020 | 4 | 0.180 |
Why?
| | Lung | 1 | 2014 | 4060 | 0.170 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 30 | 0.170 |
Why?
| | Databases, Factual | 2 | 2025 | 1357 | 0.170 |
Why?
| | Animals | 23 | 2022 | 36940 | 0.170 |
Why?
| | Intestinal Diseases | 1 | 2020 | 42 | 0.170 |
Why?
| | Arbovirus Infections | 1 | 2020 | 21 | 0.170 |
Why?
| | Meningitis, Viral | 1 | 2020 | 21 | 0.170 |
Why?
| | Peptide Fragments | 3 | 1999 | 706 | 0.170 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 976 | 0.170 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 21 | 0.170 |
Why?
| | Circulating MicroRNA | 1 | 2020 | 24 | 0.170 |
Why?
| | Medical Records | 2 | 2018 | 177 | 0.160 |
Why?
| | Myositis | 1 | 2020 | 52 | 0.160 |
Why?
| | Influenza Vaccines | 1 | 2005 | 539 | 0.160 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 45 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 202 | 0.160 |
Why?
| | Machine Learning | 1 | 2025 | 493 | 0.160 |
Why?
| | Length of Stay | 3 | 2020 | 1215 | 0.160 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.160 |
Why?
| | Consciousness Disorders | 1 | 2019 | 20 | 0.160 |
Why?
| | Adult | 20 | 2023 | 37929 | 0.160 |
Why?
| | Arthritis, Infectious | 1 | 2020 | 69 | 0.160 |
Why?
| | Receptors, Lipoprotein | 1 | 1999 | 6 | 0.160 |
Why?
| | Epithelial Cells | 3 | 2015 | 1096 | 0.150 |
Why?
| | Hepatitis | 1 | 2019 | 48 | 0.150 |
Why?
| | Amino Acid Sequence | 5 | 2016 | 2139 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5131 | 0.150 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.150 |
Why?
| | Neurocysticercosis | 1 | 2018 | 8 | 0.150 |
Why?
| | Heart Defects, Congenital | 1 | 2006 | 842 | 0.150 |
Why?
| | Abdomen | 1 | 2019 | 125 | 0.150 |
Why?
| | HEK293 Cells | 3 | 2016 | 730 | 0.150 |
Why?
| | Vero Cells | 2 | 2015 | 69 | 0.140 |
Why?
| | Immunoglobulin G | 2 | 2020 | 893 | 0.140 |
Why?
| | Body Fluids | 1 | 2018 | 66 | 0.140 |
Why?
| | Methyltransferases | 1 | 2018 | 78 | 0.140 |
Why?
| | Sequence Alignment | 2 | 2016 | 343 | 0.140 |
Why?
| | Lipoproteins | 1 | 1999 | 168 | 0.140 |
Why?
| | Hepacivirus | 3 | 2017 | 261 | 0.140 |
Why?
| | Antibodies, Viral | 3 | 2020 | 625 | 0.140 |
Why?
| | Chlamydophila pneumoniae | 1 | 2017 | 13 | 0.140 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.140 |
Why?
| | Microscopy, Electron | 4 | 2015 | 443 | 0.140 |
Why?
| | Mycoplasma Infections | 1 | 2017 | 16 | 0.140 |
Why?
| | Receptors, Immunologic | 1 | 1999 | 216 | 0.140 |
Why?
| | Heparin | 1 | 2019 | 261 | 0.140 |
Why?
| | Fluorenes | 1 | 2017 | 44 | 0.140 |
Why?
| | Chronic Disease | 1 | 2023 | 1793 | 0.140 |
Why?
| | Stomach | 1 | 2017 | 110 | 0.140 |
Why?
| | Sofosbuvir | 1 | 2017 | 62 | 0.140 |
Why?
| | Intensive Care Units | 2 | 2015 | 827 | 0.140 |
Why?
| | Intubation, Gastrointestinal | 1 | 2017 | 79 | 0.130 |
Why?
| | Mouth Mucosa | 1 | 2017 | 92 | 0.130 |
Why?
| | Prognosis | 2 | 2016 | 4030 | 0.130 |
Why?
| | Specimen Handling | 1 | 2018 | 183 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 2 | 2017 | 402 | 0.130 |
Why?
| | Antibodies, Monoclonal | 2 | 2015 | 1430 | 0.130 |
Why?
| | Movement Disorders | 1 | 2017 | 58 | 0.130 |
Why?
| | Densovirus | 1 | 2016 | 4 | 0.130 |
Why?
| | Inflammation | 2 | 2018 | 2837 | 0.130 |
Why?
| | Tristetraprolin | 1 | 2016 | 8 | 0.130 |
Why?
| | Organ Transplantation | 1 | 2020 | 250 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 114 | 0.130 |
Why?
| | Benzimidazoles | 1 | 2017 | 170 | 0.130 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 17 | 0.130 |
Why?
| | Middle East Respiratory Syndrome Coronavirus | 1 | 2016 | 8 | 0.130 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 226 | 0.130 |
Why?
| | Encephalomyelitis | 1 | 2016 | 12 | 0.130 |
Why?
| | Vaccination | 1 | 2005 | 1381 | 0.130 |
Why?
| | Seizures | 1 | 2020 | 426 | 0.130 |
Why?
| | Gastrostomy | 1 | 2017 | 117 | 0.130 |
Why?
| | Urban Population | 1 | 2019 | 479 | 0.130 |
Why?
| | Protein Phosphatase 2 | 1 | 2016 | 41 | 0.130 |
Why?
| | Electromyography | 2 | 2017 | 400 | 0.130 |
Why?
| | Borderline Personality Disorder | 1 | 2016 | 15 | 0.130 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.120 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.120 |
Why?
| | Still's Disease, Adult-Onset | 1 | 1995 | 5 | 0.120 |
Why?
| | Syncope | 1 | 2016 | 52 | 0.120 |
Why?
| | Stomach Ulcer | 1 | 1995 | 14 | 0.120 |
Why?
| | Dendritic Spines | 1 | 2016 | 65 | 0.120 |
Why?
| | Bradycardia | 1 | 2016 | 55 | 0.120 |
Why?
| | Psychopathology | 1 | 2016 | 56 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2014 | 4193 | 0.120 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 27 | 0.120 |
Why?
| | Hepatitis C, Chronic | 1 | 2017 | 164 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2016 | 242 | 0.120 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2015 | 14 | 0.120 |
Why?
| | Lyme Disease | 1 | 2016 | 60 | 0.120 |
Why?
| | Bacterial Proteins | 2 | 2018 | 879 | 0.120 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 24 | 0.120 |
Why?
| | Sapovirus | 1 | 2015 | 1 | 0.120 |
Why?
| | Cephalosporins | 1 | 2015 | 48 | 0.120 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 283 | 0.120 |
Why?
| | Rotavirus | 1 | 2015 | 20 | 0.120 |
Why?
| | Colonoscopy | 1 | 2017 | 245 | 0.120 |
Why?
| | Rural Population | 1 | 2019 | 563 | 0.120 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 145 | 0.120 |
Why?
| | Peritonitis | 1 | 1995 | 84 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 871 | 0.120 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 445 | 0.120 |
Why?
| | Virus Shedding | 1 | 2015 | 48 | 0.120 |
Why?
| | Norovirus | 1 | 2015 | 26 | 0.120 |
Why?
| | Health Resources | 1 | 2016 | 120 | 0.110 |
Why?
| | Mother-Child Relations | 1 | 2016 | 137 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1129 | 0.110 |
Why?
| | RNA Viruses | 1 | 2015 | 43 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2015 | 171 | 0.110 |
Why?
| | Bacterial Shedding | 1 | 2014 | 3 | 0.110 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 108 | 0.110 |
Why?
| | Zanamivir | 1 | 2014 | 1 | 0.110 |
Why?
| | Recurrence | 1 | 2017 | 1060 | 0.110 |
Why?
| | Echocardiography | 2 | 2019 | 642 | 0.110 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 1066 | 0.110 |
Why?
| | Cost of Illness | 1 | 2016 | 308 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 622 | 0.110 |
Why?
| | Oseltamivir | 1 | 2014 | 12 | 0.110 |
Why?
| | Infection Control | 1 | 2015 | 167 | 0.110 |
Why?
| | Parainfluenza Virus 4, Human | 1 | 2013 | 2 | 0.110 |
Why?
| | Dogs | 1 | 2015 | 413 | 0.110 |
Why?
| | Republic of Korea | 2 | 2025 | 37 | 0.110 |
Why?
| | Molecular Typing | 1 | 2013 | 22 | 0.110 |
Why?
| | Anomie | 1 | 2013 | 3 | 0.110 |
Why?
| | Disease Reservoirs | 1 | 2013 | 21 | 0.110 |
Why?
| | Giant Cells | 1 | 2013 | 24 | 0.110 |
Why?
| | Particulate Matter | 1 | 2016 | 315 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 350 | 0.100 |
Why?
| | Stress Disorders, Traumatic | 1 | 2013 | 22 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2016 | 455 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 815 | 0.100 |
Why?
| | Brazil | 1 | 2013 | 167 | 0.100 |
Why?
| | Pediatrics | 3 | 2020 | 1101 | 0.100 |
Why?
| | Social Adjustment | 1 | 2013 | 62 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 167 | 0.100 |
Why?
| | Mexico | 1 | 2013 | 225 | 0.100 |
Why?
| | Middle Aged | 17 | 2020 | 33479 | 0.100 |
Why?
| | Oxygen | 2 | 2023 | 931 | 0.100 |
Why?
| | Neuroimaging | 1 | 2014 | 259 | 0.100 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 321 | 0.100 |
Why?
| | Membrane Proteins | 1 | 1999 | 1164 | 0.100 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 40 | 0.100 |
Why?
| | Age Factors | 4 | 2010 | 3295 | 0.100 |
Why?
| | Glucocorticoids | 2 | 2013 | 594 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 233 | 0.090 |
Why?
| | Brain | 3 | 2018 | 2668 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 382 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 356 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 679 | 0.090 |
Why?
| | Biomarkers | 3 | 2021 | 4149 | 0.090 |
Why?
| | Environmental Exposure | 1 | 2016 | 579 | 0.090 |
Why?
| | Models, Theoretical | 2 | 2025 | 578 | 0.090 |
Why?
| | Illinois | 2 | 2015 | 43 | 0.090 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 286 | 0.090 |
Why?
| | Inpatients | 1 | 2015 | 500 | 0.090 |
Why?
| | Bulbourethral Glands | 1 | 2010 | 1 | 0.090 |
Why?
| | Seminal Vesicles | 1 | 2010 | 10 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 114 | 0.090 |
Why?
| | Urogenital System | 1 | 2010 | 17 | 0.080 |
Why?
| | Intestines | 1 | 2013 | 357 | 0.080 |
Why?
| | Peptides | 1 | 2016 | 985 | 0.080 |
Why?
| | Macrophages, Alveolar | 1 | 2013 | 391 | 0.080 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 697 | 0.080 |
Why?
| | Mothers | 1 | 2016 | 754 | 0.080 |
Why?
| | Aspirin | 1 | 2013 | 387 | 0.080 |
Why?
| | Receptors, Androgen | 1 | 2010 | 150 | 0.080 |
Why?
| | Cell Line | 5 | 2017 | 2847 | 0.080 |
Why?
| | Prostate | 1 | 2010 | 175 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2013 | 778 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 1993 | 1692 | 0.080 |
Why?
| | Cholesteatoma | 1 | 1988 | 10 | 0.070 |
Why?
| | Ear Diseases | 1 | 1988 | 15 | 0.070 |
Why?
| | Mental Health Services | 1 | 2013 | 421 | 0.070 |
Why?
| | Cleft Palate | 1 | 1988 | 68 | 0.070 |
Why?
| | Disease Transmission, Infectious | 2 | 2005 | 62 | 0.070 |
Why?
| | Liver Diseases | 1 | 2011 | 315 | 0.070 |
Why?
| | Stress, Psychological | 1 | 2016 | 1100 | 0.070 |
Why?
| | Adrenal Medulla | 1 | 2007 | 9 | 0.070 |
Why?
| | Chromaffin Cells | 1 | 2007 | 4 | 0.070 |
Why?
| | Lipoproteins, LDL | 2 | 1999 | 116 | 0.070 |
Why?
| | Diagnostic Errors | 1 | 2008 | 170 | 0.070 |
Why?
| | Arthritis, Rheumatoid | 1 | 2016 | 1167 | 0.070 |
Why?
| | Mice | 8 | 2022 | 17787 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1993 | 683 | 0.070 |
Why?
| | Head and Neck Neoplasms | 1 | 1993 | 606 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1724 | 0.070 |
Why?
| | Patient Admission | 1 | 2008 | 197 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 786 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2006 | 90 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1993 | 1079 | 0.060 |
Why?
| | Odds Ratio | 2 | 2021 | 1070 | 0.060 |
Why?
| | Scotland | 1 | 2025 | 18 | 0.060 |
Why?
| | Photoperiod | 2 | 2010 | 52 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 26 | 0.060 |
Why?
| | Immunoassay | 1 | 2006 | 115 | 0.060 |
Why?
| | Serogroup | 1 | 2025 | 44 | 0.060 |
Why?
| | Sexually Transmitted Diseases, Viral | 1 | 2005 | 10 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 2019 | 564 | 0.060 |
Why?
| | Klebsiella pneumoniae | 1 | 2025 | 47 | 0.060 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2025 | 78 | 0.060 |
Why?
| | Aged | 8 | 2020 | 23961 | 0.060 |
Why?
| | Chicago | 1 | 2004 | 61 | 0.060 |
Why?
| | Population Surveillance | 1 | 2008 | 482 | 0.060 |
Why?
| | Homosexuality | 1 | 2004 | 17 | 0.060 |
Why?
| | Fibroblasts | 3 | 2016 | 996 | 0.060 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Models, Molecular | 3 | 2017 | 1570 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 2 | 2020 | 565 | 0.050 |
Why?
| | Bacterial Capsules | 1 | 2003 | 30 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2005 | 184 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2181 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2691 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2031 | 0.050 |
Why?
| | Streptococcus | 1 | 2023 | 28 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 275 | 0.050 |
Why?
| | Risk Assessment | 2 | 2019 | 3457 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2023 | 346 | 0.050 |
Why?
| | Minnesota | 1 | 2023 | 164 | 0.050 |
Why?
| | Computational Biology | 2 | 2019 | 644 | 0.050 |
Why?
| | Respiratory System | 1 | 2023 | 157 | 0.050 |
Why?
| | Heparin Lyase | 2 | 1999 | 5 | 0.050 |
Why?
| | Immunization Schedule | 1 | 2003 | 197 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 673 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 25 | 0.050 |
Why?
| | New Zealand | 1 | 2021 | 56 | 0.050 |
Why?
| | Italy | 1 | 2021 | 110 | 0.050 |
Why?
| | Immunization Programs | 1 | 2003 | 213 | 0.050 |
Why?
| | History, 21st Century | 1 | 2022 | 213 | 0.050 |
Why?
| | Embryo, Mammalian | 2 | 1999 | 232 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2021 | 148 | 0.040 |
Why?
| | Schools | 1 | 2004 | 461 | 0.040 |
Why?
| | Sertoli Cells | 1 | 2001 | 26 | 0.040 |
Why?
| | Conserved Sequence | 2 | 1998 | 239 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 82 | 0.040 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 23 | 0.040 |
Why?
| | Oropharynx | 1 | 2020 | 46 | 0.040 |
Why?
| | Societies, Medical | 1 | 2005 | 820 | 0.040 |
Why?
| | Serologic Tests | 1 | 2020 | 54 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 295 | 0.040 |
Why?
| | Receptors, LDL | 2 | 1998 | 47 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2020 | 90 | 0.040 |
Why?
| | Lithium | 1 | 2000 | 43 | 0.040 |
Why?
| | Discriminant Analysis | 1 | 2020 | 37 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 89 | 0.040 |
Why?
| | Comorbidity | 2 | 2021 | 1622 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 28 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 128 | 0.040 |
Why?
| | Macrophages | 2 | 2016 | 1547 | 0.040 |
Why?
| | Anti-Ulcer Agents | 1 | 1999 | 16 | 0.040 |
Why?
| | Testis | 1 | 2000 | 151 | 0.040 |
Why?
| | Adrenal Cortex | 1 | 1999 | 29 | 0.040 |
Why?
| | Spermatozoa | 1 | 2000 | 94 | 0.040 |
Why?
| | Chlorates | 1 | 1999 | 4 | 0.040 |
Why?
| | Immunocompetence | 1 | 2019 | 42 | 0.040 |
Why?
| | Sesquiterpenes | 1 | 1999 | 55 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2000 | 148 | 0.040 |
Why?
| | Scavenger Receptors, Class B | 1 | 1999 | 14 | 0.040 |
Why?
| | Scavenger Receptors, Class A | 1 | 1999 | 12 | 0.040 |
Why?
| | Egtazic Acid | 1 | 1999 | 40 | 0.040 |
Why?
| | Receptors, Scavenger | 1 | 1999 | 23 | 0.040 |
Why?
| | Lactones | 1 | 1999 | 56 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 18 | 0.040 |
Why?
| | Reproduction | 1 | 2001 | 204 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 849 | 0.040 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 113 | 0.040 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2019 | 106 | 0.040 |
Why?
| | Seminiferous Epithelium | 1 | 1998 | 1 | 0.040 |
Why?
| | Lipoproteins, HDL | 1 | 1999 | 77 | 0.040 |
Why?
| | Europe | 1 | 2020 | 414 | 0.040 |
Why?
| | Lactams | 1 | 1998 | 20 | 0.040 |
Why?
| | Parasites | 1 | 2019 | 50 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 184 | 0.040 |
Why?
| | Plasma | 1 | 2020 | 212 | 0.040 |
Why?
| | Blood | 1 | 1999 | 107 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 410 | 0.040 |
Why?
| | Child Health Services | 1 | 2020 | 184 | 0.040 |
Why?
| | Health Personnel | 1 | 2005 | 710 | 0.040 |
Why?
| | Spermatogenesis | 1 | 1998 | 67 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 169 | 0.040 |
Why?
| | Patient Discharge | 1 | 2025 | 897 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2020 | 338 | 0.040 |
Why?
| | Evolution, Molecular | 2 | 2016 | 493 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2020 | 184 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2018 | 329 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 152 | 0.040 |
Why?
| | Models, Biological | 1 | 2025 | 1783 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 305 | 0.040 |
Why?
| | Arboviruses | 1 | 2017 | 16 | 0.040 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 40 | 0.030 |
Why?
| | Headache | 1 | 2018 | 147 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 310 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2018 | 164 | 0.030 |
Why?
| | Models, Chemical | 1 | 1999 | 263 | 0.030 |
Why?
| | Structural Homology, Protein | 1 | 2017 | 27 | 0.030 |
Why?
| | HIV Protease Inhibitors | 1 | 2017 | 69 | 0.030 |
Why?
| | Contact Tracing | 1 | 2017 | 27 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 2018 | 106 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2017 | 62 | 0.030 |
Why?
| | Clinical Competence | 1 | 2005 | 1118 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 86 | 0.030 |
Why?
| | Colon | 1 | 1999 | 282 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 816 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2017 | 103 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 195 | 0.030 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2016 | 6 | 0.030 |
Why?
| | Macrolides | 1 | 2017 | 65 | 0.030 |
Why?
| | RNA | 1 | 2023 | 921 | 0.030 |
Why?
| | Amino Alcohols | 1 | 2016 | 2 | 0.030 |
Why?
| | Paracentesis | 1 | 1996 | 14 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2018 | 190 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 184 | 0.030 |
Why?
| | Genomics | 1 | 2022 | 795 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 40 | 0.030 |
Why?
| | Colitis | 1 | 1999 | 266 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 452 | 0.030 |
Why?
| | Ascites | 1 | 1996 | 46 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2016 | 82 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 17 | 0.030 |
Why?
| | Eosinophilia | 1 | 2018 | 218 | 0.030 |
Why?
| | Urban Health | 1 | 2016 | 92 | 0.030 |
Why?
| | Membrane Fusion | 1 | 2016 | 39 | 0.030 |
Why?
| | Dextrans | 1 | 1996 | 84 | 0.030 |
Why?
| | Pyramidal Cells | 1 | 2016 | 74 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 192 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 123 | 0.030 |
Why?
| | Serine | 1 | 2016 | 141 | 0.030 |
Why?
| | Naproxen | 1 | 1995 | 17 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2019 | 513 | 0.030 |
Why?
| | Missouri | 1 | 2015 | 61 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2017 | 476 | 0.030 |
Why?
| | Prednisolone | 1 | 1995 | 83 | 0.030 |
Why?
| | Synovial Membrane | 1 | 2016 | 117 | 0.030 |
Why?
| | Facial Expression | 1 | 2016 | 72 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 289 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 549 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2057 | 0.030 |
Why?
| | Epitopes | 1 | 2017 | 479 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 552 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 394 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 149 | 0.030 |
Why?
| | Systole | 1 | 2015 | 189 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2015 | 125 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 810 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2016 | 192 | 0.030 |
Why?
| | Cough | 1 | 2015 | 122 | 0.030 |
Why?
| | Cote d'Ivoire | 1 | 2014 | 9 | 0.030 |
Why?
| | Vietnam | 1 | 2014 | 28 | 0.030 |
Why?
| | beta Catenin | 1 | 2016 | 253 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 320 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 364 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 94 | 0.030 |
Why?
| | Biodiversity | 1 | 2018 | 409 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 287 | 0.030 |
Why?
| | Protein Binding | 2 | 2017 | 2224 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 1996 | 316 | 0.030 |
Why?
| | Gene Order | 1 | 2013 | 26 | 0.030 |
Why?
| | Liberia | 1 | 2013 | 8 | 0.030 |
Why?
| | Cell Membrane | 2 | 2013 | 738 | 0.030 |
Why?
| | Social Control, Formal | 1 | 2013 | 12 | 0.030 |
Why?
| | Lentivirus | 1 | 2013 | 56 | 0.030 |
Why?
| | Trypsin | 1 | 2013 | 77 | 0.030 |
Why?
| | California | 1 | 2015 | 431 | 0.030 |
Why?
| | Dyspnea | 1 | 2015 | 254 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1468 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 411 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2016 | 379 | 0.030 |
Why?
| | Mesna | 1 | 1993 | 16 | 0.030 |
Why?
| | Warfare | 1 | 2013 | 68 | 0.030 |
Why?
| | Ifosfamide | 1 | 1993 | 37 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2016 | 377 | 0.030 |
Why?
| | Alopecia | 1 | 1993 | 32 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1477 | 0.020 |
Why?
| | Synapses | 1 | 2016 | 427 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1587 | 0.020 |
Why?
| | Exanthema | 1 | 2013 | 78 | 0.020 |
Why?
| | Endosomes | 1 | 2013 | 136 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2013 | 163 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1710 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 560 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 391 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1759 | 0.020 |
Why?
| | HIV-1 | 1 | 2017 | 864 | 0.020 |
Why?
| | Antiemetics | 1 | 1992 | 43 | 0.020 |
Why?
| | Nausea | 1 | 1992 | 111 | 0.020 |
Why?
| | Needs Assessment | 1 | 2013 | 376 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 2011 | 43 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2015 | 645 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2016 | 785 | 0.020 |
Why?
| | Pregnancy | 2 | 2020 | 6763 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2069 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2011 | 90 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 97 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1266 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2011 | 157 | 0.020 |
Why?
| | Urethra | 1 | 2010 | 55 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 150 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1991 | 87 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 390 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 3015 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 618 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1035 | 0.020 |
Why?
| | Iowa | 1 | 1988 | 30 | 0.020 |
Why?
| | Otitis Media with Effusion | 1 | 1988 | 20 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2189 | 0.020 |
Why?
| | Rats, Wistar | 2 | 2000 | 455 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2833 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1502 | 0.020 |
Why?
| | Cytokines | 1 | 2016 | 2085 | 0.020 |
Why?
| | Mental Disorders | 1 | 2016 | 1077 | 0.020 |
Why?
| | Capsid Proteins | 1 | 2008 | 94 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1397 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 786 | 0.020 |
Why?
| | Catecholamines | 1 | 2007 | 98 | 0.020 |
Why?
| | Hepatitis C Antigens | 1 | 2006 | 1 | 0.020 |
Why?
| | Hepatitis C Antibodies | 1 | 2006 | 11 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2006 | 219 | 0.020 |
Why?
| | Qualitative Research | 1 | 2013 | 1386 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4295 | 0.020 |
Why?
| | Rats | 3 | 2000 | 5647 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5757 | 0.010 |
Why?
| | Viral Proteins | 1 | 2008 | 342 | 0.010 |
Why?
| | France | 1 | 2005 | 33 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2006 | 125 | 0.010 |
Why?
| | Sexuality | 1 | 2005 | 31 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 3958 | 0.010 |
Why?
| | Safe Sex | 1 | 2004 | 23 | 0.010 |
Why?
| | Syphilis | 1 | 2004 | 32 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 7635 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1738 | 0.010 |
Why?
| | Asthma | 1 | 2015 | 2295 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1199 | 0.010 |
Why?
| | Cyclophosphamide | 2 | 1992 | 247 | 0.010 |
Why?
| | Organelles | 1 | 2001 | 58 | 0.010 |
Why?
| | Sperm Motility | 1 | 2000 | 32 | 0.010 |
Why?
| | Cell Count | 1 | 2001 | 324 | 0.010 |
Why?
| | Trinitrobenzenesulfonic Acid | 1 | 1999 | 10 | 0.010 |
Why?
| | Zona Fasciculata | 1 | 1999 | 1 | 0.010 |
Why?
| | Acetic Acid | 1 | 1999 | 18 | 0.010 |
Why?
| | Colloids | 1 | 2000 | 60 | 0.010 |
Why?
| | Irritants | 1 | 1999 | 43 | 0.010 |
Why?
| | Doxorubicin | 2 | 1992 | 362 | 0.010 |
Why?
| | Melatonin | 1 | 2000 | 150 | 0.010 |
Why?
| | Spermatogonia | 1 | 1998 | 13 | 0.010 |
Why?
| | Spermatids | 1 | 1998 | 21 | 0.010 |
Why?
| | Organ Size | 1 | 1999 | 477 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1998 | 149 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1998 | 145 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1998 | 374 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1998 | 570 | 0.010 |
Why?
| | Polysaccharide-Lyases | 1 | 1996 | 11 | 0.010 |
Why?
| | Ascitic Fluid | 1 | 1996 | 15 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 202 | 0.010 |
Why?
| | Half-Life | 1 | 1996 | 164 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1996 | 171 | 0.010 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 1998 | 340 | 0.010 |
Why?
| | Body Weight | 1 | 2000 | 985 | 0.010 |
Why?
| | Reference Values | 1 | 1996 | 816 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1092 | 0.010 |
Why?
| | Sex Factors | 1 | 2000 | 2071 | 0.010 |
Why?
| | Protein Conformation | 1 | 1996 | 934 | 0.010 |
Why?
| | Binding Sites | 1 | 1996 | 1303 | 0.010 |
Why?
| | Thiethylperazine | 1 | 1992 | 1 | 0.010 |
Why?
| | Amitriptyline | 1 | 1992 | 21 | 0.010 |
Why?
| | Methylprednisolone | 1 | 1992 | 86 | 0.010 |
Why?
| | Procarbazine | 1 | 1991 | 9 | 0.010 |
Why?
| | Neurons | 1 | 2000 | 1590 | 0.010 |
Why?
| | Fluorouracil | 1 | 1992 | 208 | 0.010 |
Why?
| | Leucovorin | 1 | 1991 | 81 | 0.010 |
Why?
| | Etoposide | 1 | 1991 | 158 | 0.010 |
Why?
| | Vincristine | 1 | 1991 | 116 | 0.010 |
Why?
| | Prednisone | 1 | 1991 | 240 | 0.010 |
Why?
| | Methotrexate | 1 | 1991 | 260 | 0.000 |
Why?
| | Liver | 1 | 1996 | 1943 | 0.000 |
Why?
|
|
Dominguez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|